SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

HEXO Corp. HEXO NASDAQ

NASDAQ Capital Marke • Healthcare • Drug Manufacturers - Specialty & Generic • CA • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

HEXO Corp. (HEXO) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.71. It has a SharesGrow Score of 18/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $191M, +59.2%/yr average growth. Net income is $1.1B (loss), growing at -442.2%/yr. Net profit margin is -561.8% (negative). Gross margin is -39.6% (-96.2 pp trend).

Balance sheet: total debt is $252M against $314M equity (Debt-to-Equity (D/E) ratio 0.8, moderate). Current ratio is 0.81 (tight liquidity). Debt-to-assets is 36.9%. Total assets: $681M.

Analyst outlook: 0 / 5 analysts rate HEXO as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 17/100 (Fail), Moat 8/100 (Fail), Future 20/100 (Fail), Income 10/100 (Fail).

HEXO SharesGrow Score Overview

23/100

SharesGrow Score

Below average — proceed with caution

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 58/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 17/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 8/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — HEXO

No analyst coverage available for this stock.

HEXO: +59.2%/yr revenue is, -442.2%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet HEXO: Debt-to-Equity (D/E) ratio 0.8 (moderate), Current ratio is 0.81 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

HEXO: Gross margin is -39.6% (-96.2 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 8/100. ≥ 70 = Pass.

View details →

Analyst outlook: 0 / 5 analysts rate HEXO as buy (0%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

HEXO: Net profit margin is -561.8%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.66-3.836

Volume298.45K

Avg Volume (30D)323.3K

Market Cap$31.24M

Beta (1Y)2.13

Share Statistics

EPS (TTM)-38.68

Shares Outstanding$27.76M

IPO Date2017-03-23

CEOCharlie Bowman

Financial Highlights & Ratios

Revenue (TTM)$191.1M

Gross Profit$-75.67M

EBITDA$-257.63M

Net Income$-1.07B

Operating Income$-1.07B

Total Cash$83.24M

Total Debt$251.52M

Net Debt$168.28M

Total Assets$680.95M

Price / Earnings (P/E)-0

Price / Sales (P/S)0.16

Analyst Forecast

Rating ConsensusHold

Analysts Covering5

Buy 0% Hold 60% Sell 40%

Company Info

CountryCA

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINCA4283041099

Price Chart

HEXO

HEXO Corp. ↗ · NASDAQ Capital Marke

Healthcare • Drug Manufacturers - Specialty & Generic

0.66 52WK RANGE 3.84

People Also View

Curaleaf Holdings, Inc.

Cronos Group Inc.

Tilray Brands, Inc.

Canopy Growth Corporation

Aurora Cannabis Inc.

Organigram Global Inc.

Eli Lilly and Company

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message